TIDMMDC
RNS Number : 7640V
Mediclinic International plc
25 July 2018
Mediclinic International plc
(Incorporated in England and Wales)
Company Number 8338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic" or "the Company")
25 July 2018
DIRECTORATE CHANGES
APPOINTMENT OF DR ANJA OSWALD AS AN INDEPENDENT NON-EXECUTIVE
DIRECTOR
Mediclinic announces that Dr Anja Oswald is to join its Board as
an independent non-executive director with effect from 25 July
2018.
Dr Edwin Hertzog, Chairman of Mediclinic, commented:
"The Board is delighted to welcome Dr Oswald as an independent
non-executive director of the Company. Her expertise in the Swiss
healthcare system, health politics and the regulatory environment,
surgical medicine, general management and the development of
business strategies will be valuable additions to the Board."
Dr Oswald is the CEO of the Klinik Sonnenhalde, a
well-established private clinic for psychiatry and psychotherapy
with inpatients, day-care clinics and outpatients in Riehen,
Switzerland and is Vice-President of the Association of Private
Hospitals in Basel. Prior to this, she was Head of Medical and
Pharmaceutical Services and Deputy Medical Officer in the
Department of Health of the Cantonal Government in Basel and a
member of various cantonal, regional and national committees. Dr
Oswald was also CEO of a start-up company in the health care sector
and worked several years as a Medical Doctor in different
hospitals.
Dr Oswald holds a Masters in Business Administration from the
Rochester-Berne Executive MBA, a Doctorate in Medicine from the
University of Basel specialising in orthopaedic surgery and
traumatology as well as in sports medicine. She passed the Board
School at the International Centre of Corporate Governance of the
University of St. Gallen.
There are no disclosures required pursuant to paragraphs (1) to
(6) of LR 9.6.13 R of the UK Listing Authority's Listing Rules in
respect of this appointment. Dr Oswald's fees will amount to
GBP80,000 per annum, including the fees payable for committee
memberships referred to in more detail below, which is in line with
current independent non-executive directors.
CHANGES TO COMMITTEE MEMBERSHIPS
The Board also agreed to certain other changes to the membership
of its committees. As announced on 29 March 2018, following the
resignations of Ms Nandi Mandela and Prof Dr Robert Leu as
independent non-executive directors at the conclusion of the Annual
General Meeting to be held today, their memberships of all Board
committees will cease at that point. Accordingly, the Company
confirms the following Board committee changes:
Remuneration Committee:
With effect from 25 July 2018, Prof Dr Robert Leu will step down
as a member of the Remuneration Committee and Dr Anja Oswald will
be appointed as a member of the Remuneration Committee.
Nomination Committee:
With effect from 25 July 2018, Prof Dr Robert Leu and Mr Trevor
Petersen will step down as members of the Nomination Committee and
will be replaced on that committee by Dr Felicity Harvey and Dr
Anja Oswald.
Clinical Performance and Sustainability Committee:
With effect from 25 July 2018, Prof Dr Robert Leu, Mr Danie
Meintjes and Ms Nandi Mandela will step down as members of the
Clinical Performance and Sustainability Committee. Mr Seamus
Keating and Dr Ronnie van der Merwe will become members of the
Clinical Performance and Sustainability Committee from that
date.
Investment Committee:
With effect from 25 July 2018, Mr Seamus Keating will step down
as a member of the Investment Committee and Dr Ronnie van der Merwe
will be appointed as a member of the Investment Committee.
About Mediclinic International plc
Mediclinic is an international private healthcare services group
with operating divisions in Switzerland, Southern Africa (South
Africa and Namibia) and the United Arab Emirates. Its core purpose
is to enhance the quality of life of patients by providing acute
care, specialist-orientated, multi-disciplinary healthcare
services. Mediclinic also holds a 29.9% interest in Spire
Healthcare Group plc, an LSE-listed and UK-based private healthcare
group.
Mediclinic comprises 75 hospitals and 30 clinics. Hirslanden
operates 17 private acute care facilities and 4 clinics in
Switzerland with more than 1 800 inpatient beds; Mediclinic
Southern Africa operates 49 hospitals and 2 day clinics throughout
South Africa and 3 hospitals in Namibia with more than 8 100
inpatient beds in total; and Mediclinic Middle East operates 6
hospitals and 24 clinics with more than 700 inpatient beds in the
United Arab Emirates.
Mediclinic has a primary listing on the Main Market of the LSE
in the United Kingdom, with secondary listings on the JSE in South
Africa and the NSX in Namibia.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Jayne Meacham / Caroline Emmet
+44 (0)20 7954 9569
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Brett Pollard/Debbie Scott - UK
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V
7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc
JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank
Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAPGUCPMUPRGWA
(END) Dow Jones Newswires
July 25, 2018 09:45 ET (13:45 GMT)
Mediclinic (LSE:MDC)
Historical Stock Chart
From Apr 2024 to May 2024
Mediclinic (LSE:MDC)
Historical Stock Chart
From May 2023 to May 2024